Arcadia Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M | $8.0M | $1.2M | $1.5M |
| Cost of Revenue | $3.1M | $3.0M | $2.2M | $6.1M | $8.7M | $5.2M | — | — |
| Gross Profit | $1.8M | $2.1M | $2.3M | $1.3M | $-1.9M | $2.8M | — | — |
| Gross Margin | 36.2% | 41.3% | 51.2% | 17.8% | -28.4% | 35.3% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $9.0K | $53.0K | $64.0K | $1.5M | $3.9M | $8.0M | $7.1M | $6.1M |
| SG&A Expense | $7.0M | $9.6M | $8.2M | $15.0M | $22.9M | $16.5M | $13.6M | $11.6M |
| Operating Income | $-2.5M | $-3.6M | $-6.1M | $-14.0M | $-35.5M | $-12.8M | $-19.4M | $-16.9M |
| Operating Margin | -51.5% | -72.3% | -137.0% | -188.8% | -524.0% | -159.0% | -1,657.9% | -1,152.3% |
| Interest Expense | — | — | — | — | $20.0K | $47.0K | $5.0K | — |
| Pretax Income | $-2.3M | $-4.3M | $-5.3M | $-10.8M | $-16.1M | $-6.2M | $-28.9M | $-13.5M |
| Income Tax Expense | $8.0K | $8.0K | $8.0K | $14.0K | $2.0K | $-124.0K | $2.0K | $10.0K |
| Net Income | $-2.3M | $-7.0M | $-14.0M | $-15.4M | $-14.7M | $-4.7M | $-28.8M | $-13.5M |
| Net Margin | -48.1% | -139.5% | -313.9% | -207.3% | -216.2% | -57.9% | -2,464.1% | -920.8% |
| EPS (Basic) | $-1.71 | $-5.17 | $-11.29 | $-12.83 | $-13.78 | $-0.24 | $-2.27 | $-1.79 |
| EPS (Diluted) | $-1.71 | $-5.17 | $-11.29 | $-12.83 | $-13.78 | $-0.24 | $-2.27 | $-1.79 |
| Shares Outstanding (Basic) | 1.4M | 1.4M | 1.2M | 1.2M | 1.1M | 26.9M | 17.3M | 9.5M |
| Shares Outstanding (Diluted) | 1.4M | 1.4M | 1.2M | 1.2M | 1.1M | 26.9M | 17.3M | 9.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |